As basic research findings are translated into clinical practice, the promise of delivering personalizedmedicine based on genomic information is increasingly being fulfilled. Two themes arise in the area ofcancer: 1) Risk-stratification before disease manifests to optimize prevention and early detection strategies,and after disease manifests to inform treatment decisions; and 2) The impact of testing algorithms (e.g.,testing accuracy, sequencing, and timing) on subsequent management.Our objectives are to develop tools to address the clinical and economic information gaps regarding thevalue of genomic diagnostics and therapies for personalized medicine.
Specific aims are to:
Aim 1 : Develop a generalized framework using flexible, modular cost-effectiveness analysis models toaddress three key issues specific to personalized medicine in cancer:t Key issue #1: Risk stratification to optimize treatment and early detection, as illustrated by (a) UsingGEP in patients with BC to predict the risk of recurrence and guide treatment; and (b) Using genomictesting to risk-stratify and guide screening and surveillance in patients with CRC who may be affectedby Lynch syndrome and in their relatives. Key issue #2: Testing algorithms designed to guide targeted therapy, as illustrated by the impact ofalternative tests for HER2, test sequencing, and timing on guiding targeted therapy with trastuzumab(Herceptin , Genentech) in early-stage BC. Key issue #3: Impact of risk-stratification on individuals and their family members, as illustrated bythe example of testing for possible Lynch syndrome in relatives without cancer.
Aim 2 : Estimate the effectiveness and cost-effectiveness of using genomic information in the applications ofpersonalized medicine stated in Aim 1 by populating the decision models with unique data from ProgramProjects.
Aim 3 : Inform health policy and clinical decisions by characterizing the uncertainty in the model inputs,estimating the decision uncertainty, and calculating the potential value of undertaking additional research toreduce this uncertainty by using state-of-the-art value-of-information methods.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA130818-01A1
Application #
7515632
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2008-07-01
Project End
2011-06-30
Budget Start
2008-09-16
Budget End
2009-08-31
Support Year
1
Fiscal Year
2008
Total Cost
$190,625
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Phillips, Kathryn A; Deverka, Patricia A; Sox, Harold C et al. (2017) Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genet Med 19:1081-1091
Knight, Sara J; Mohamed, Ateesha F; Marshall, Deborah A et al. (2015) Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample. Med Decis Making :
Ponce, Ninez A; Ko, Michelle; Liang, Su-Ying et al. (2015) Early diffusion of gene expression profiling in breast cancer patients associated with areas of high income inequality. Health Aff (Millwood) 34:609-15
Kilambi, Vikram; Johnson, F Reed; González, Juan Marcos et al. (2014) Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening. Value Health 17:838-45
Phillips, Kathryn A; Ann Sakowski, Julie; Trosman, Julia et al. (2014) The economic value of personalized medicine tests: what we know and what we need to know. Genet Med 16:251-7
Phillips, Kathryn A; Labno, Anna (2014) Private Companies Providing Health Care Price Data: Who Are They and What Information do They Provide? J Manag Care Med 17:75-80
Pletcher, Mark J; Pignone, Michael; Earnshaw, Stephanie et al. (2014) Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes 7:276-84
Ferrusi, Ilia L; Earle, Craig C; Trudeau, Maureen et al. (2013) Closing the personalized medicine information gap: HER2 test documentation practice. Am J Manag Care 19:838-44
Kuppermann, Miriam; Wang, Grace; Wong, Shirley et al. (2013) Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome. Cancer 119:215-25
Weitzel, Jeffrey N; Clague, Jessica; Martir-Negron, Arelis et al. (2013) Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol 31:210-6

Showing the most recent 10 out of 43 publications